Raphael Pharma Reports Zero Revenue, Confirms Urgent Need for Significant Financing in Q1
RAPH filed a Earnings and Guidance on light trading volume (0.1× avg).
Summary
Raphael Pharmaceutical Inc. reported Q1 2026 results with zero revenue and a net loss of $229K, or $(0.01) per share, an improvement from the prior year's loss. This 10-Q filing reinforces the severe financial distress previously highlighted in the company's last 10-K, which included a going concern warning. Despite operational progress, including positive results from a rheumatoid arthritis study, a product launch, and a patent filing, the company explicitly states it has minimal cash and requires significant financing to fund operations through 2026. This continued liquidity crunch is a major concern for investors, overshadowing the operational advancements. Investors will be closely monitoring for any announcements regarding new financing or strategic partnerships to address the critical cash needs.
At the time of this announcement, RAPH was trading at $1.40 on OTC in the Life Sciences sector, with a market capitalization of approximately $28.2M. The 52-week trading range was $0.04 to $2.50. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.